Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Cypher PMA filed

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Cordis filed for an in-stent restenosis indication for the sirolimus-eluting stent, firm announces May 11. Data from the 384-patient SISR trial showed that patients with blockage in previously implanted bare-metal stents who received Cypher stents had a lower incidence of target vessel failure than patients who underwent brachytherapy. Brachytherapy, or radiation from within the vessel, is the only FDA-approved treatment for in-stent restenosis. Competitor Boston Scientific's Taxus paclitaxel-eluting stent also showed positive results for the indication in the Taxus V clinical trial (1"The Gray Sheet" March 20, 2006, p. 6)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel